What's new with type 2 diabetes care in 2021?

65 minutes to Watch
Contributor
Dr Ryan Paul
4 March 2021
What's new with type 2 diabetes care in 2021? - Dr Ryan Paul

Dr Ryan Paul is an academic endocrinologist at Waikato DHB and the University of Waikato. He is current president of the New Zealand Society of Endocrinology (NZSE) and an executive member of the New Zealand Society for the Study of Diabetes (NZSSD).

Log in, CAPTURE your learning and add to your professional development records.

What you can expect

In this video, Dr Paul discusses the updates to type 2 diabetes care in 2021. The webinar covers:

  • The updated treatment algorithm of type 2 diabetes in New Zealand.
  • When and how to use SGLT2 inhibitors and GLP-1 receptor agonists.
  • Who does and who does not meet the Special Authority criteria for funded SGLT2 inhibitors and GLP-1 receptor agonists.
  • New recommendations for the screening and management of type 2 diabetes in Aotearoa New Zealand.
  • Case discussion.

Downloadable empagliflozin patient information is available at:


This video was recorded from live webinars hosted by Mobile Health on 18 and 24 February 2021, attended predominantly by rural health professionals. The video has been edited for clarity.

You can also watch this video on ELearning by clicking the "LET'S LEARN" button below.

This activity has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes.

Presentation slides

To view Dr Paul's slides from a similar presentation, click here.

Question and answers

For a transcription of the Q&A from this webinar and a similar session run by The Goodfellow Unit, click here.

Want to learn more?

Click below to complete the related ELearning course.

Let's Learn